Tradename: HYQVIA
Proper Name: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Indication: To extend the indication of Primary Immunodeficiency Diseases to pediatric patients from 2 years of age ≤ 16 years of age.
Indicated for the treatment of Primary Immunodeficiency (PI) in adults and pediatric patients two years of age and older.
Approval Date: 04/07/2023
Manufacturer: Baxalta US Inc.
More: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/hyqvia